Association of TRDMT1 Gene Polymorphisms With Neuroblastoma Susceptibility: Insights From a Case-Control Study

Area of Science:

• Genetics
• Oncology
• Epigenetics

Background:

• Neuroblastoma is the most common pediatric extracranial solid tumor, with genetic factors contributing to its development.
• The role of tRNA Dimethyltransferase 1 (TRDMT1), a key enzyme in RNA methylation, in neuroblastoma susceptibility was previously unexplored.

Purpose of the Study:

• To investigate the association between TRDMT1 gene polymorphisms and neuroblastoma susceptibility in a Chinese population.
• To explore the impact of these polymorphisms on TRDMT1 expression and their correlation with clinical features and prognosis.

Main Methods:

• A case-control study involving 402 neuroblastoma patients and 473 controls.
• Genotyping of TRDMT1 polymorphisms (rs7074891, rs10904887, rs2273734) using the TaqMan assay.
• Statistical analyses including logistic regression, stratification, expression quantitative trait locus (eQTL), clinical correlation, and survival analyses.

Main Results:

• The rs7074891 TC/CC genotype was associated with reduced neuroblastoma risk, particularly in younger children and those with mediastinal tumors.
• Conversely, rs10904887 CC and rs2273734 TT genotypes were linked to increased neuroblastoma risk, with specific effects in subgroups like males and older children.
• TRDMT1 polymorphisms influenced TRDMT1 expression, with higher expression correlating with poorer prognosis and high-risk clinical features.

Conclusions:

• TRDMT1 polymorphisms are significantly associated with neuroblastoma susceptibility and risk.
• These findings provide insights into the genetic and epigenetic mechanisms underlying neuroblastoma.
• TRDMT1 polymorphisms may serve as potential biomarkers for neuroblastoma risk stratification and therapeutic targets.